Effect of N-acetylcysteine on exacerbations of bronchiectasis (BENE): a randomized controlled trial

Qian Qi 1,2, Yirepanjaing Ailiyaer 3, Ruijuan Liu 4, Yan Zhang 5, Caiyu Li 6, Mingtao Liu 7, Xiuxiu Wang 1, Lijun Jing 1 and Yu Li 1*

Abstract

Background: N-acetylcysteine is a classic mucolytic agent. This study aimed to investigate the efficacy of N-acetylcysteine on reducing the risk of exacerbations in bronchiectasis patients.

Methods: A prospective, randomized, controlled trial was conducted between April 1, 2014 and December 31, 2016 in five general hospitals in Shandong Province, China. Adult bronchiectasis patients with at least two exacerbations in the past year were potentially eligible. Patients were randomly assigned to receive oral N-acetylcysteine (600 mg, twice daily, 12 months) or on-demand treatment.

Results: A total of 161 patients were eligible for randomization (81 to the N-acetylcysteine group and 80 to the control group). During the 12-month follow-up, the incidence of exacerbations in the N-acetylcysteine group was significantly lower than that in the control group (1.31 vs. 1.98 exacerbations per patient-year; risk ratio, 0.41; 95% CI, 0.17–0.66; P = 0.0011). The median number of exacerbations in the N-acetylcysteine group was 1 (0.5–2), compared with 2 (1–2) in the control group (U = −2.95, P = 0.003). A total of 24.7% of the N-acetylcysteine group patients and 11.3% of the control group patients remained exacerbation-free throughout the 12-month follow-up (χ² = 4.924, P = 0.026). Compared with the control group, the volume of 24-h sputum in the N-acetylcysteine group was significantly reduced (t = −3.091, P = 0.002). Additionally, the N-acetylcysteine group showed a significant improvement in the quality of life. No severe adverse events were reported in the intervention group.

Conclusion: The long-term use of N-acetylcysteine is able to reduce the risk of exacerbations for bronchiectasis patients in Shandong Province, China. The results of this study should be verified in a larger randomized controlled trial.

Trial registration: ClinicalTrials.gov (NCT02088216) (Registered date: March 5, 2014).

Keywords: N-acetylcysteine, Bronchiectasis, Long-term therapy, Exacerbations

Introduction

Bronchiectasis is a chronic suppurative lung disease characterized by permanent dilation of bronchi and bronchioles [1]. The number of hospital admissions due to bronchiectasis are increasing [2]. Pathophysiologically, the hypertrophy of mucus-secreting glands leads to excessive secretion of mucus into the airway. The normal clearance of the mucociliary system is compromised in patients with bronchiectasis, resulting in pooling of mucus within the airway [3]. Excessive secretion and retention of mucus in the airway results in a chronic cough and continuous expectoration in patients with bronchiectasis. Inflammatory reactions, injury and distortion of bronchi, mucus retention, and respiratory infection or bacterial colonization are the four major components of the “vicious cycle” underlying the pathogenesis of bronchiectasis [4, 5]. The population of patients with bronchiectasis is extremely heterogeneous. Aliberti et al. [6] reported that “dry bronchiectasis” is an established clinical phenotype (27% of patients), and
none of these patients had chronic infections or daily sputum production. The other three clusters of bronchiectasis were characterized by the presence of chronic infection with *Pseudomonas aeruginosa* or other pathogens and daily sputum production [6]. Mucus production plays an essential role in the other three clusters of bronchiectasis. It has been deduced that reducing the production of mucus or improving the clearance of sputum in the airway is the key to break down this “vicious cycle” and enhance the therapeutic efficacy for bronchiectasis.

Mucoactive drugs are commonly used to clear the airway in mucus hypersecretion diseases [7]. Mucoactive agents, such as hypertonic saline, mannitol, and erdosteine, have greatly improved the treatment outcomes for bronchiectasis. It was found that a short-term regimen of erdosteine plus routine chest physiotherapy decreased mucus hypersecretion in stable patients with bronchiectasis [8]. Another clinical trial showed that the inhalation of dry powder mannitol for 12 weeks significantly reduced the amount of sputum in bronchiectasis patients [9]. Unfortunately, these trials were limited by their small sample sizes and short treatment period. A systematic review on the efficacy of mucolytics for bronchiectasis indicated that the level of evidence supporting the routine use of mucoactive agents for bronchiectasis was low [10]. Therefore, large randomized controlled trials are needed to generate high level evidence on the efficacy of the long-term use of mucolytics for reducing the risk of exacerbations in patients with bronchiectasis.

Currently, investigators have found that N-acetylcysteine, an effective mucolytic agent, not only reduces the viscosity and elasticity of sputum, but it also has anti-inflammatory and antioxidant activity [11, 12]. Moreover, N-acetylcysteine has shown a protective effect against the detrimental impact of lipopolysaccharide in vitro [13]. In addition, a randomized, placebo-controlled trial with a large sample size demonstrated that a high dose of oral N-acetylcysteine (1200 mg/day) for 1 year significantly reduced the rate of exacerbations and improved the quality of life in patients with chronic obstructive pulmonary disease (COPD) [14, 15]. Additionally, the Spanish guidelines on the treatment of bronchiectasis indicate that the use of N-acetylcysteine should be considered for patients with bronchiectasis and COPD [16]. Furthermore, Oliveria et al. found that the oxidative stress biomarkers of adult bronchiectasis patients were significantly elevated in both cellular and plasma extracts [17], suggesting that oxidative stress plays an important role in the pathophysiological changes of bronchiectasis. Therefore, as a classic mucolytic agent with antioxidant and anti-inflammatory properties, N-acetylcysteine can be effective in the treatment of bronchiectasis.

In this study, we aimed to assess whether the long-term use of oral N-acetylcysteine (600 mg, twice daily) might reduce the rate of exacerbations and improve the quality of life in patients with bronchiectasis.

**Materials and methods**

**Study subjects**

Bronchiectasis was diagnosed based on the clinical manifestations and imaging features of high-resolution computed tomography scans (HRCT), including the internal lumen diameter of the bronchi being greater than that of the accompanying pulmonary artery, the bronchi failing to taper in the periphery of the chest, or the bronchi terminating in a cyst [5]. The underlying etiology of bronchiectasis was determined after performing a panel of investigations according to the 2010 British Thoracic Society guidelines for bronchiectasis and our previous studies on the etiology of bronchiectasis [5, 18]. Patients were screened for potential eligibility in five general hospitals in Shandong Province, China, from April 1, 2014 to December 31, 2016. The inclusion criteria were as follows: 1) subjects aged between 18 and 80 years old; 2) a diagnosis of idiopathic or post-infective bronchiectasis was made according to Qi et al. [18]; and 3) patients had at least two exacerbations in the past year and were in a stable state for at least 4 weeks prior to randomization. Patients were excluded if they fulfilled any of the following criteria: current smokers; cigarette smoking within 6 months; cystic fibrosis or other etiologies (such as immunodeficiency, allergic bronchopulmonary aspergillosis, traction bronchiectasis caused by emphysema, advanced pulmonary fibrosis, etc.); pulmonary function test results showing a forced expiratory volume in 1 s (FEV$_1$) ≤ 30% of the predicted value; primary diagnosis of COPD or asthma; a history of severe cardiovascular disease; comorbidity with liver disease, kidney disease, malignant tumor, gastric ulcer, or intestinal malabsorption; a known allergy to N-acetylcysteine; pregnancy or lactation (for women); a history of prior macrolide use of more than 1 week; and poor compliance. This study was registered at ClinicalTrials.gov (NCT020888216) and was approved by the ethics committees of the five participating hospitals. Informed consents were obtained from all patients.

**Study design**

The Effect of N-acetylcysteine on Exacerbations of Bronchiectasis (BENE) study was a prospective, randomized, controlled, multicenter clinical trial. The main study objective was to assess whether the long-term use of oral N-acetylcysteine (600 mg, twice daily, 12 months) might reduce the incidence of exacerbations and improve the quality of life in patients with bronchiectasis. According to previous clinical data on exacerbations of...
bronchiectasis [18] and the inclusion criteria of this study that a subpopulation of bronchiectasis patients with at least two exacerbations in the past year were included, we hypothesized that the baseline frequency of exacerbations was 3. Due to the lack of clinical data on the efficiency of N-acetylcysteine in the treatment of bronchiectasis, we estimated that approximately 154 patients would need to be enrolled in this study to have 80% power to detect a reduction of at least 33% in the yearly exacerbation incidence, assuming a two-sided α level of 0.05 and 20% attrition.

Methods
The disease severity of bronchiectasis was evaluated according to a validated severity classification system for bronchiectasis—the Bronchiectasis Severity Index (BSI) [19]. The sequence was generated by a computer, and the patients who met the criteria were allocated in a 1:1 ratio to receive either oral N-acetylcysteine (600 mg, twice daily) or control (receive as-needed therapy) for 12 months. All the participants were followed for up to 12 months. N-acetylcysteine was provided for patients of the N-acetylcysteine group each month to potentially promote treatment adherence, and telephone calls from the study site were used to remind the patients of treatment and to check for treatment compliance. Outpatient and/or telephone visits were obtained for the primary and secondary outcomes at 1, 3, 6, 9, and 12 months. Each visit included assessment of respiratory signs and symptoms, a physical examination, adverse events, compliance, and exacerbations of bronchiectasis, etc. When patients suffered from exacerbations of bronchiectasis, the treatment strategy based on current guidelines was instituted [20]. Meanwhile, patients in the N-acetylcysteine group were also required to receive oral N-acetylcysteine (600 mg, twice daily) during the study period. For the control group, interventions would be discontinued once the patient recovered from the exacerbation. Maintenance therapies that had already started in patients with pulmonary ventilation dysfunction prior to enrollment, such as short-acting bronchodilators, long-acting bronchodilators, inhaled glucocorticoids, or theophylline, were continued during the study.

Study end-points
The primary end-point was the incidence of exacerbations in a year, defined as the number of all exacerbations associated with bronchiectasis within 1 year. According to a consensus definition for clinical research, an exacerbation of bronchiectasis is defined as a bronchiectasis patient with a deterioration in three or more key symptoms (including cough, sputum volume and/or consistency, sputum purulence, breathlessness and/or exercise tolerance, fatigue and/or malaise, and hemoptysis) for at least 48 h and a clinician determining that a change in bronchiectasis treatment is required [21]. Details regarding symptoms of an exacerbation such as cough, sputum volume (collected over 24 h), sputum properties, breathlessness, fatigue and hemoptysis were documented by site investigators from all centers.

Secondary end-points included the percentage of patients remaining exacerbation-free throughout the 12-month follow-up, the time to first exacerbation, the time to second exacerbation, 24-h sputum volume, pulmonary function, inflammation indices, quality of life as assessed by the COPD assessment test (CAT) score [22], and adverse events. The CAT score is a valid and reproducible instrument in patients with bronchiectasis, presenting a good correlation with clinical, functional, and quality-of-life measurements [23]. It has been validated in a bronchiectasis patient population and was used to determine the quality of life of bronchiectasis patients in this study. The volume of 24-h sputum was measured by a graduated cylinder marked in milliliters. Eligible sputum samples were used for testing sputum microbiological culture and antibiotic resistance. Pulmonary function was assessed three times before recruitment, and the maximum value was used for analysis. Following treatment, pulmonary function was reassessed for forced vital capacity (FVC), FEV1, percentage of predicted FEV1, FEV1/FVC ratio (FEV1/FVC), and inspiratory capacity, etc. Inflammatory markers including serum C-reactive protein (CRP) and the erythrocyte sedimentation rate (ESR) were tested at each visit. The number of lobes involved was counted, and the degree of bronchiectasis was quantified by HRCT according to the modified Reiff grade [24]. Furthermore, the degree of dyspnea was assessed by the modified Medical Research Council (mMRC) scale [25].

Statistical analyses
Patients who received at least one assessment visit after randomization were left in the original group for analysis of the results. Continuous data were expressed as the mean ± standard deviation and were compared using the Student's t test. Categorical variables were expressed as a number (%) and were compared using the χ² test. The number of exacerbations was described by the median (interquartile range, IQR). The Mann-Whitney U test was performed to compare the difference in the number of exacerbations between the two groups. The primary study end point was the incidence of exacerbations, which is a count and follows Poisson distribution. Negative binomial regression not including other covariates was employed to compute the risk ratio and 95% confidence intervals (CIs) for N-acetylcysteine vs. the control. The time to first exacerbation and the time to
second exacerbation were described by Kaplan–Meier curves, and the log-rank test was used to explore the differences in the time to first exacerbation and the time to second exacerbation between the two groups. All analyses were conducted with the Statistical Package for the Social Sciences software (version 20.0). A $p$ value < 0.05 was considered statistically significant.

**Results**

**Patients**

A total of 326 subjects were screened in this study, and 161 subjects underwent randomization from April 1, 2014 to December 31, 2016 (Fig. 1). Eighty-one of them received treatment with oral N-acetylcysteine, and 80 were in the control group. Twenty-two patients (13.7%) were excluded from the final analysis due to dropout, including 12 in the intervention group and 10 in the control group (14.8% vs. 12.5%; $\chi^2 = 0.183$, $P = 0.669$). The reasons for dropout are shown in Fig. 1. In the N-acetylcysteine group, one patient died of acute ischemic stroke and one patient died from acute exacerbation of bronchiectasis. In the control group, one patient died of coronary artery disease and two patients died from acute exacerbations of bronchiectasis. No deaths were considered by the investigators to be related to the study drugs. Finally, 69 patients (85.2%) in the N-acetylcysteine group and 70 patients (87.5%) in the control group completed the study. The baseline characteristics, including sex, age, body mass index, smoking history, etiology of bronchiectasis, HRCT grade, extent of the lesion lobes, mMRC score, CAT score, 24-h sputum volume, sputum culture of *P. aeruginosa* positive, number of exacerbations in the last year, inflammatory indices, lung function parameters, and BSI, were not significantly different between the intervention and control groups (Table 1). Additionally, baseline medications were not significantly different between the two groups (Table 1).

**Efficacy**

**Primary end-point**

Eighty-one patients in the N-acetylcysteine group and 80 patients in the control group were included in the primary outcome analysis. The numbers of cumulative exacerbations for the two groups at the 12-month follow-up were 106 (the N-acetylcysteine group) and 158 (the control group), respectively. The incidence of exacerbations in the N-acetylcysteine group was significantly lower than that in the control group (1.31 vs. 1.98 exacerbations per patient-year; risk ratio, 0.41; 95% CI, 0.17–0.66; $P = 0.0011$). The median number of exacerbations in the N-acetylcysteine group was 1 (IQR, 0.5–2),
| Characteristic                      | Control group (N = 80) | N-acetylcysteine group (N = 81) | P-value |
|------------------------------------|------------------------|---------------------------------|---------|
| Gender                             |                        |                                 |         |
| Female, n (%)                      | 52 (65.0)              | 45 (55.6)                       | 0.144   |
| Age, years                         | 56.56 ± 12.41          | 53.28 ± 11.90                   | 0.089   |
| Body mass index, kg/m²              | 22.16 ± 4.22           | 22.72 ± 3.57                    | 0.362   |
| Ex-smoker, n (%)                   | 8 (10.0)               | 6 (7.4)                         | 0.381   |
| mMRC score (≥2)                    | 48 (60.0)              | 45 (55.6)                       | 0.341   |
| CAT score                          | 19.55 ± 7.26           | 19.15 ± 7.12                    | 0.723   |
| 24-h sputum volume, mL             | 28.84 ± 40.94          | 29.74 ± 41.35                   | 0.890   |
| Etiology of bronchiectasis         |                        |                                 | 0.179   |
| Postinfectious                     | 38 (47.5)              | 30 (37.0)                       |         |
| Idiopathic                         | 42 (52.5)              | 51 (63.0)                       |         |
| HRCT grade, n (%)                  |                        |                                 | 0.194   |
| 1                                  | 28 (35.0)              | 27 (33.3)                       |         |
| 2                                  | 41 (51.2)              | 34 (42.0)                       |         |
| 3                                  | 11 (13.8)              | 20 (24.7)                       |         |
| Number of lesion lobes, n (%)      |                        |                                 | 0.822   |
| 1 lobe                             | 15 (18.8)              | 18 (22.2)                       |         |
| 2–3 lobes                          | 47 (58.8)              | 44 (54.3)                       |         |
| 4–6 lobes                          | 18 (22.5)              | 19 (23.5)                       |         |
| Cystiform bronchiectasis, n (%)    |                        |                                 | 0.097   |
| 33 (41.2)                          | 44 (54.3)              |                                |         |
| Pseudomonas aeruginosa positive, n (%) | 20 (25.0)   | 27 (33.3)                       | 0.245   |
| Medications, n (%)                 |                        |                                 |         |
| Inhaled corticosteroids and long-acting β-agonist | 45 (56.2) | 56 (69.1) | 0.091 |
| Inhaled short-acting β-agonist     | 20 (25.0)              | 15 (18.5)                       | 0.391   |
| Inhaled anticholinergics           | 22 (27.5)              | 24 (29.6)                       | 0.765   |
| Inhaled corticosteroids            | 17 (21.2)              | 11 (13.6)                       | 0.199   |
| Prednisone                         | 2 (2.5)                | 3 (3.8)                         | 1.000   |
| Theophylline                       | 6 (7.5)                | 4 (5.0)                         | 0.746   |
| Pulmonary function                 |                        |                                 |         |
| FVC, L                             | 2.42 ± 0.94            | 2.32 ± 0.74                     | 0.483   |
| FEV₁, L                            | 1.56 ± 0.81            | 1.62 ± 0.73                     | 0.629   |
| Predicted FEV₁, %                  | 63.63 ± 26.28          | 60.23 ± 27.32                   | 0.451   |
| FEV₁/FVC, %                        | 64.39 ± 14.63          | 67.44 ± 16.49                   | 0.226   |
| Inspiratory capacity, L           | 1.77 ± 0.70            | 1.88 ± 0.81                     | 0.368   |
| ESR, mm/h                          | 25.39 ± 19.86          | 27.53 ± 24.07                   | 0.540   |
| CRP, mg/dL                         | 16.99 ± 21.26          | 13.37 ± 17.12                   | 0.246   |
| Number of exacerbations in the last year | 2 (2–3)            | 2 (2–3)                         | 0.713   |
| Bronchiectasis Severity Index      | 8.00 ± 4.27            | 8.43 ± 4.68                     | 0.548   |

Data are n (%) or mean ± SD or median (IQR). Abbreviations: mMRC modified Medical Research Council, CAT chronic obstructive pulmonary disease assessment test, HRCT high resolution computed tomography, FVC forced vital capacity, FEV₁ forced expiratory volume in 1 s, ESR erythrocyte sedimentation rate, CRP C-reactive protein.
compared with 2 (IQR, 1–2) in the control group (U = −2.95, P = 0.003 by the Mann-Whitney U test) (Fig. 2).

Secondary end-points

A total of 24.7% of the N-acetylcysteine group patients and 11.3% of the control group patients remained exacerbation-free throughout the 12-month follow-up period (χ² = 4.924, P = 0.026). The time to the first exacerbation did not differ between the N-acetylcysteine group and the control group (χ² = 3.795, P = 0.0515, Fig. 3). However, the time to the second exacerbation was longer in the N-acetylcysteine group than in the control group (χ² = 6.849, P = 0.0089, Fig. 4). Compared with the control group, the volume of 24-h sputum in the N-acetylcysteine group was significantly reduced (t = −3.091, P = 0.002) (Table 2). In addition, the N-acetylcysteine group showed a significant improvement in the quality of life (t = −2.57, P = 0.011) (Table 2). However, there was no significant difference between the two groups in terms of the change of the number of patients with a positive sputum culture for P. aeruginosa from the baseline. The changes of inflammatory markers, including the serum CRP levels and ESR, during the study period were not significantly different between the two groups. Similarly, there were no significant differences in lung function between the two groups.

Adverse events

The most common adverse events observed in this study are shown in Table 3. After treatment with N-acetylcysteine, three patients experienced mild elevation of liver enzymes and two patients had a rash, which were relieved by application of hepatoprotective or antiallergic agents. Serious adverse events were not observed during the study period. In addition, five patients in the N-acetylcysteine group complained of body odor during the treatment. It is likely that the odor of hydrogen sulfide was released after the decomposition of N-acetylcysteine in the gastrointestinal tract. The appearance of symptoms such as nausea, vomiting, and epigastric discomfort may also be related to this decomposition.

Discussion

The results of this study showed that oral N-acetylcysteine treatment for 1 year in patients with bronchiectasis was associated with a reduction in the incidence of exacerbations compared with the control group in Shandong Province, China. In addition to the protective effect of N-acetylcysteine against exacerbations, this treatment at a dose of 600 mg twice daily had the advantages of reducing the volume of sputum and improving the quality of life of the bronchiectasis patients.
It is reported that the average frequency of exacerbations for bronchiectasis ranges from 1.5 to 6.5 per year [5]. Frequent exacerbations have a negative impact on long-term clinical outcomes for bronchiectasis patients, including lung function deterioration, increased risk of hospitalization, and increased medical costs [26, 27]. Therefore, there is an urgent need for clinical research dedicated to reducing the frequency of exacerbations. More recently, numerous studies have focused on the long-term use of macrolides for the treatment of bronchiectasis. Several major trials, including EMBRACE, BLESS, and BAT, consistently showed the efficiency of macrolides (azithromycin or erythromycin) in reducing the frequency of exacerbations in patients with bronchiectasis [28–30]. However, the long-term use of macrolides increased the risk of bacterial resistance, with a high incidence of adverse events. More importantly, the rate of macrolide resistance and the incidence of gastrointestinal adverse effects in patients treated with azithromycin were 88 and 40%, respectively [30]. Therefore, the safety profile of a treatment strategy should also be considered in the management of bronchiectasis.

Impairment of the mucociliary system in bronchiectasis patients is responsible for the excessive secretion of mucus and long-term retention of the sputum. Recently, increasing numbers of studies have focused on mucoactive agents. European Respiratory Society guidelines recommend offering long-term mucoactive treatment (≥3 months) in adult patients with bronchiectasis [20]. However, RhDNase is not recommended by either the European Respiratory Society guidelines or the British Thoracic Society guidelines because there is evidence that rhDNase use is associated with worsening lung function in bronchiectasis [5, 20]. The quality of life was found to be improved by the use of mannitol or hypertonic saline in a subgroup of patients with bronchiectasis.
Furthermore, Bilton et al. reported that the time to first exacerbation was prolonged in patients receiving mannitol as compared with the controls [32]. However, few clinical research studies have reported the efficacy of mucolytic agents on the prevention of exacerbations in bronchiectasis patients. One reason might be the short-term therapy employed in previous trials, and another reason is that a certain subgroup of bronchiectasis patients might benefit more from mucoactive drugs. To the best of our knowledge, studies on the long-term use of N-acetylcysteine for the treatment of bronchiectasis have not been reported. In contrast to previous studies focusing on the use of other mucolytic agents in the treatment of bronchiectasis, the present study investigated N-acetylcysteine because it is not only an effective mucolytic agent but also has anti-inflammatory and antioxidant properties.

The role of N-acetylcysteine has been widely investigated in many studies involving patients with COPD. Although our results indicated that the time to the first exacerbation did not differ between the N-acetylcysteine group and the control group, significantly more patients remained exacerbation-free in the N-acetylcysteine group than in the control group. Furthermore, the time to the second exacerbation was longer in the N-acetylcysteine group than in the control group. Consistent with the COPD studies, our study found that the long-term use of oral N-acetylcysteine (600 mg, twice daily, 12 months) prevented exacerbations in patients with bronchiectasis in Shandong Province, China, accompanied by a decrease of the daily sputum volume and improvement in the quality of life. We supposed that the underlying mechanism of N-acetylcysteine in preventing exacerbations might be mediated via the reduced volume of sputum so that the “vicious cycle” was broken down. Furthermore, the anti-inflammatory and antioxidant properties of N-acetylcysteine were also responsible for the results. In addition, evidence from in vitro studies indicates that N-acetylcysteine has the ability to interfere with biofilm formation and disrupt biofilms so that the survivability of bacteria in the respiratory tract can be inhibited [34].

Table 2

| Adverse event                        | Control group (N = 80) | N-acetylcysteine group (N = 81) | P value |
|--------------------------------------|------------------------|---------------------------------|---------|
| Epigastric discomfort                | 6 (7.5%)               | 8 (9.9%)                        |         |
| Abdominal pain                       | 2 (2.5%)               | 2 (2.5%)                        |         |
| Vomit                                | 4 (5%)                 | 1 (1.3%)                        |         |
| Body odor                            | 0                      | 5 (6.2%)                        |         |
| Anorexia or nausea                   | 8 (10%)                | 7 (8.6%)                        |         |
| Diarrhea                             | 3 (3.8%)               | 1 (1.2%)                        |         |
| Rash                                 | 1 (1.3%)               | 2 (2.5%)                        |         |
| Dyspnea                              | 5 (6.3%)               | 2 (2.5%)                        |         |
| Hepatic dysfunction                  | 2 (2.5%)               | 3 (3.7%)                        |         |

Data are n (%) or mean ± SD. Abbreviations: CAT chronic obstructive pulmonary disease assessment test, FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, ESR erythrocyte sedimentation rate, CRP C-reactive protein.
the quality of life of the patients have nothing to do with the bronchodilation effect. Similar to other clinical studies regarding the long-term use of N-acetylcysteine, our study found that long-term N-acetylcysteine therapy was safe. A low incidence of adverse reactions was reported in patients with bronchiectasis, indicating that N-acetylcysteine was well tolerated. In addition, it has been reported that N-acetylcysteine-related adverse drug reactions are mainly associated with anaphylactoid reactions to N-acetylcysteine [35]. Anaphylactoid reactions are non-immunogenic and do not require prior sensitization. The precise mechanisms of these reactions remain unclear, although non-mast cell sources of histamine are likely to play a role [36]. Body odor and gastrointestinal adverse reactions were found in our study, but they did not affect the overall efficacy of N-acetylcysteine. Of note, the use of N-acetylcysteine can avoid the problems of gastrointestinal adverse reactions and bacterial drug resistance caused by long-term azithromycin therapy [30].

To the best of our knowledge, this BENE study was the first trial to explore the efficacy and safety of long-term use of N-acetylcysteine for the treatment of bronchiectasis in China. However, this study had several limitations. First, the subjects were enrolled from the same province in China, reflecting a rather homogenous population of bronchiectasis patients. There is some geographical variation in etiology, epidemiology, and microbiology of bronchiectasis [37]. Besides, inconsistent diagnostic criteria were used to study the etiology of bronchiectasis. As a result, the proportion of idiopathic bronchiectasis patients in the Chinese population [18, 38] seems to be higher than that in the Spanish registry, which reported that only 24% were idiopathic [39]. The prognosis and management of bronchiectasis might differ between various geographic regions. Therefore, the effect of N-acetylcysteine on a Chinese population might differ from that in other populations. Along with the small sample size, these factors may influence the results. Hence, larger trials of heterogenous populations of bronchiectasis patients are needed to validate our results. Second, this study did not compare N-acetylcysteine to a placebo. Thus, there is a concern for bias. For example, N-acetylcysteine might also have been used in the control group. In addition, both researchers and patients were not blinded to the interventions, which may introduce the placebo effect. Due to these methodological flaws, the recommendation of long-term use of N-acetylcysteine in bronchiectasis cannot be made until the current results are validated in larger international multicenter trials. Third, this study did not analyze the therapeutic effects of N-acetylcysteine separately for “dry bronchiectasis,” “daily sputum,” or other subtypes of bronchiectasis. Since sputum production and chronic infection were less frequent in the “dry bronchiectasis” cluster, it is unclear whether the “dry bronchiectasis” group would benefit from the long-term use of N-acetylcysteine. Subgroup analysis of bronchiectasis according to microbiology and daily sputum suggests that different clinical phenotypes of bronchiectasis might exhibit diverse treatment outcomes in the same trial [6]. Different clinical phenotypes may require different treatments. Further studies are needed to explore how they are affected by treatment. Finally, nebulized N-acetylcysteine might be an effective way to deliver the drug, in contrast to oral administration, which involves first-pass liver metabolism and may result in a decreased efficacy or an increased toxicity. Further studies are needed to explore the efficacy and safety of nebulized N-acetylcysteine for bronchiectasis patients.

In conclusion, the long-term use of N-acetylcysteine is able to reduce the risk of exacerbations for bronchiectasis patients in Shandong Province, China. This trial may lead to larger international multicenter research in the field.

Abbreviations
BSI: Bronchiectasis Severity Index; CAT: COPD assessment test; CIs: Confidence intervals; COPD: Chronic obstructive pulmonary disease; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; FEV1: Forced expiratory volume in 1 s; FVC: Forced vital capacity; HRCT: High-resolution computed tomography scans; IQR: Interquartile range; mMRC: Modified Medical Research Council

Acknowledgments
Not applicable.

Funding
There was no funding in this study.

Availability of data and materials
The datasets analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
QQ designed the study, wrote the manuscript, and substantively revised the manuscript. YA designed the study and wrote the manuscript. RL, YZ, CL and ML collected the data. XW and LJ analyzed the data. YL designed the study, wrote the manuscript, and substantively revised the manuscript. All of the authors read and approved the final manuscript.

Ethics approval and consent to participate
The study was approved by the Ethics Committee of Qilu Hospital of Shandong University (clinical trial registration No. NCT02088216). All patients gave written informed consent for participation in this study.

Consent for publication
All patients’ data were collected with consent from individual patient at the time of enrollment throughout data collection period.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
5. Pasteur MC, Bilton D, Hill AT. British Thoracic Society bronchiectasis non-CF
6. Aliberti S, Lonni S, Dore S, McDonnell MJ, Goeminne PC, Dimakou K, et al.
4. Flume PA, Chalmers JD. Advances in bronchiectasis: endotyping, genetics,
1. McShane PJ, Naureckas ET, Tino G, Strek ME. Non-cystic fibrosis

References
1. McShane PJ, Naureckas ET, Tino G, Strek ME. Non-cystic fibrosis
2. Garcia-Olive I, Marin A, Rodriguez-Pons L, Abad J. Trends in admission for
3. Nair GB, Ilowite JS. Pharmacologic agents for mucus clearance in
4. Flume PA, Chalmers JD. Advances in bronchiectasis: endotyping, genetics,
5. Pasteur MC, Bilton D, Hill AT. British Thoracic Society bronchiectasis non-CF
6. Aliberti S, Lonni S, Dore S, McDonnell MJ, Goeminne PC, Dimakou K, et al.
7. Chalmers JD, Polverino E. European Respiratory Society Bronchiectasis
Guidelines Task Force. Macrolides, mucoactive drugs and adherence for the
management of bronchiectasis. Eur Respir J. 2016;47:1113–22.
8. Chalmers JD, Polverino E. European Respiratory Society Bronchiectasis
Guidelines Task Force. Macrolides, mucoactive drugs and adherence for the
management of bronchiectasis. Eur Respir J. 2016;47:1113–22.
9. Cisulli E, Coletti O, Costi S, Zanasi E, Lorenzi C, Lucic S, et al. Effectiveness of
erodine in elderly patients with bronchiectasis and hypereosinopenia: a 15-day,
prospective, parallel, open-label, pilot study. Clin Ther. 2007;29:2001–9.
10. Bilton D, Davidias E, Anderson SD, Kolbe J, King G, Stirling RG, et al. Phase 3
randomized study of the efficacy and safety of inhaled dry powder
mannitol for the symptomatic treatment of non-cystic fibrosis
bronchiectasis. Chest. 2013;144:215–25.
11. Wilkinson M, Sugumar K, Milan SJ, Hart A, Crockett A, Crossingham I.
Mucolytics for bronchiectasis. Cochrane Database Syst Rev. 2014;5:
CD001289. https://doi.org/10.1002/14651858.CD001289.pub2.
12. Moitra S. N-acetylcysteine (NAC) in COPD: benefits often lost in trials. QJM.
2018;https://doi.org/10.1093/qjmed/hqy1166.
13. Cazzola M, Caltetta L, Facchini F, Rogliani P, Matera MG. Pharmacological
investigation on the anti-oxidant and anti-inflammatory activity of N-
acetylcysteine in an ex vivo model of COPD exacerbation. Respir Res.
2017;18:26.
14. Caltetta L, Rogliani P, Facchini F, Rinaldi B, Cazzola M, Matera MG. N-
acetylcysteine protects human bronchi by modulating the release of
urokinase in an ex vivo model of COPD exacerbation. Biomed
Pharmacother. 2018;103:1–8.
15. Zheng JP, Wen FQ, Bao CX, Wan HY, Kang J, Chen P, et al. High-dose N-
acetylcysteine in the prevention of COPD exacerbations: rationale and
design of the PANTHEON study. COPD. 2013;10:164–71.
16. Zheng JP, Wen FQ, Bao CX, Wan HY, Kang J, Chen P, et al. Twice daily N-
acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary
disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
Lancet Respir Med. 2014;2:187–94.
17. Martinez-Garcia MA, Maiz L, Oliveira C, Giron RM, de la Rosa D, Blanco M, et al. Spanish
guidelines on treatment of bronchiectasis in adults. Arch Bronconeumol.
2018;54(2):88–98.
18. Oliveira C, Oliveira C, Donado A, Garcia-Fuentes E, Rubio E, Tinahones F, et al. Cellular and plasma oxidative stress biomarkers are raised in adults with
bronchiectasis. Clin Nutr. 2013;32:112–7.
19. Qi Q, Wang W, Li T, Zhang Y, Li Y. Aetiology and clinical characteristics of
patients with bronchiectasis in a Chinese Han population: a prospective
study. Respiratory. 2015;20:917–24.
20. Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, et al. The bronchiectasis severity index. An international derivation and
validation study. Am J Respir Crit Care Med. 2014;189:576–85.
21. Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Leebinger
MR, et al. European Respiratory Society guidelines for the management of
adult bronchiectasis. Eur Respir J. 2017;50(3).
22. Hill AT, Haworth CS, Aliberti S, Barker A, Blasi F, Boerma W, et al. Pulmonary
exacerbation in adults with bronchiectasis: a consensus definition for clinical
research. Eur Respir J. 2017;49(6).
23. Gupta N, Pinto LM, Morigan A, Bourbeau J. The COPD assessment test: a
systematic review. Eur Respir J. 2014;44:873–84.
24. Lanza FC, Castro RAS, de Camargo AA, Zanatta DJM, Rached S, Athanazio R,
et al. COPD assessment test (CAT) is a valid and simple tool to measure the
impact of bronchiectasis on affected patients. COPD. 2018;15(5):512–9.
25. Kim S, Oh J, Kim YI, Ban HJ, Kwon YS, Oh U, et al. Differences in classification
of COPD group using COPD assessment test (CAT) or modified Medical
Research Council (mMRC) dyspnea scores: a cross-sectional analysis. BMC
Pulm Med. 2013;13:35.
26. Ma Y, Niu Y, Tian G, Wei J, Gao Z. Pulmonary function abnormalities in adult
patients with acute exacerbation of bronchiectasis: a retrospective risk
factor analysis. ChronRespir Dis. 2015;12:222–9.
27. Ringpfeilser FC, de Roux A, Plutz MW, Hamalainen N, Welte T, Radermacher
J. Bronchiectasis-associated hospitalizations in Germany, 2005-2011: a
population-based study of disease burden and trends. PLoC One. 2013:
e71109.
28. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBREAC): a randomised, double-blind, placebo-controlled
trial. Lancet. 2012;380:660–7.
29. Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, et al. Effect
of long-term, low-dose erythromycin on pulmonary exacerbations among
patients with non-cystic fibrosis bronchiectasis: the BLESS randomized
controlled trial. JAMA. 2013;309:260–7.
30. Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, et
al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the
BAT randomized controlled trial. JAMA. 2013;309:1251–9.
31. Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung
function and quality of life in bronchiectasis. Respir Med. 2011;105:1831–5.
32. Bilton D, Tino G, Barker AF, Chambers DC, de Soysa A, Dupont LJ, et al. Inhaled
mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled
trial. Thorax. 2014;69:1073–9.
33. Tse HN, Raiter L, Wong KY, Yee KS, Ng LY, Wai KY, et al. High-dose N-
acetylcysteine in stable COPD: the 1-year, double-blind, randomized,
placebo-controlled HIACE study. Chest. 2013;144:106–18.
34. Blasi F, Page C, Rossolini GM, Pallecchi L, Matera MG, Rogliani P, et al. The
effect of N-acetylcysteine on biofilms: implications for the treatment of
respiratory tract infections. Respir Med. 2016;117:190–7.
35. Jabl F. Skin rash after oral N-acetylcysteine for kidney protection. Int J
Dermatol. 2014;53:e189–90.
36. Yamamoto T, Spencer T, Dargan P, Wood DM. Incidence and management of
N-acetylcysteine-related anaphylactoid reactions during the management of
acute paracetamol overdose. Eur J Emerg Med. 2014;21:57–60.
37. Chandrasekaran R, Mac Agoin M, Chalmers JD, Elborn SJ, Chotirmall SH.
Geographic variation in the aetiology, epidemiology and microbiology of
bronchiectasis. BMC Pulm Med. 2018;18:83.
38. Guan WJ, Gao YH, Xu G, Lin ZY, Tang Y, Li HM, et al. Aetiology of
bronchiectasis in Guangzhou, southern China. Respir Med. 2015;20:739–48.
39. Oliveira C, Padilla A, Martinez-Garcia MA, de la Rosa D, Giron RM, Vendrell M,
et al. Biology of bronchiectasis in a cohort of 2047 patients. An analysis of
the Spanish historical bronchiectasis registry. Arch Bronconeumol. 2017;53:
366–74.